Jump to content

Indorenate: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
PotatoBot (talk | contribs)
Bots
51,239 edits
m Stub sorting and placement of stub template(s): nervous-system-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox valida
Line 2: Line 2:
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AV9L041QA4
| UNII = AV9L041QA4
| verifiedrevid = 437161996
| verifiedrevid = 445987050
| IUPAC_name = methyl 3-amino-2-(5-methoxy-1H-indol-3-yl)propanoate
| IUPAC_name = methyl 3-amino-2-(5-methoxy-1H-indol-3-yl)propanoate
| image= Indorenate_structure.png
| image= Indorenate_structure.png

Revision as of 19:28, 10 September 2011

Indorenate
Identifiers
  • methyl 3-amino-2-(5-methoxy-1H-indol-3-yl)propanoate
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H16N2O3
Molar mass248.277 g/mol g·mol−1
3D model (JSmol)
  • COC(=O)C(CN)c1cnc(ccc2OC)c1c2
  (verify)

Indorenate (TR-3369), is a tryptamine derivative which acts as an agonist at the 5-HT1A, 5-HT1B and 5-HT2C serotonin receptors. It has anxiolytic, antihypertensive and anorectic effects, predominantly through action at 5-HT1A, but with some contribution from the 5-HT1B and 5-HT2C subtypes, and possibly some other non-serotonergic targets also.[1][2][3][4][5][6][7][8][9]

See also


References

  1. ^ Antonaccio MJ, Kerwin L (1981). "On the effects and mechanism of action of the antihypertensive agent TR 3369 (5-methoxytryptamine beta-methylcarboxylate) in spontaneously hypertensive rats". Journal of Cardiovascular Pharmacology. 3 (6): 1306–11. PMID 6173531.
  2. ^ Schoeffter P, Hoyer D (1988). "Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus". British Journal of Pharmacology. 95 (3): 975–85. PMC 1854240. PMID 3207999. {{cite journal}}: Unknown parameter |month= ignored (help)
  3. ^ Fernández-Guasti A, Escalante A, Hong E, Agmo A (1990). "Behavioural actions of the serotonergic anxiolytic indorenate". Pharmacology, Biochemistry, and Behavior. 37 (1): 83–8. doi:10.1016/0091-3057(90)90045-J. PMID 1979877. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  4. ^ López Cabrera M, Velázquez Martínez DN, Prado R, García G, Ortiz R (1991). "Effects of the intracerebroventricular administration of indorenate and fenfluramine on spontaneous behavior and food intake in rats". Proceedings of the Western Pharmacology Society. 34: 465–8. PMID 1788330.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Velázquez-Martínez DN, López Cabrera M, Sánchez H, Ramírez JI, Hong E (1999). "Discriminative stimulus properties of indorenate, a serotonin agonist". Journal of Psychiatry & Neuroscience : JPN. 24 (2): 122–30. PMC 1188992. PMID 10212554. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Sánchez H, Velázquez-Martínez DN (2001). "Discriminative stimulus properties of indorenate, a 5-HT1A, 5-HT1B and 5-HT2C agonist: a study in rats". Journal of Psychopharmacology (Oxford, England). 15 (1): 29–36. PMID 11277605. {{cite journal}}: Unknown parameter |month= ignored (help)
  7. ^ Miranda F, Orozco G, Velázquez-Martínez DN (2002). "Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist". Behavioural Pharmacology. 13 (4): 303–11. PMID 12218511. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  8. ^ Miranda F, Hong E, Sánchez H, Velázquez-Martínez DN (2003). "Further evidence that the discriminative stimulus properties of indorenate are mediated by 5-HT 1A/1B/2C receptors". Pharmacology, Biochemistry, and Behavior. 74 (2): 371–80. doi:10.1016/S0091-3057(02)01010-9. PMID 12479957. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  9. ^ López-Meraz ML, Neri-Bazán L, Rocha L (2006). "Indorenate modifies a1-adrenergic and benzodiazepine receptor binding in the rat brain: an autoradiography study". The Journal of Pharmacy and Pharmacology. 58 (9): 1243–8. doi:10.1211/jpp.58.9.0011. PMID 16945183. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Indorenate&oldid=449583242"